Alliance for Pharmacy Compounding, 100 Daingerfield Road, Ste 100, Alexandria, VA (2026)

03/06/2026

What you need to know about med spa regs (or the absence thereof). John Hertig’s tutorial on med-spa regulation in NABP Innovations magazine, “Injecting Clarity: The State of Medical Spa Regulation in the US,” is a must-read.

🔗https://bit.ly/4b5OyfJ

Trying to clear some confusion in Virginia. We recently submitted a letter to the Virginia Board of Pharmacy seeking clarification on its enforcement approach to compounded GLP-1 medications. Specifically, we’re concerned that the BoP’s actions appear inconsistent with both FDA guidance and Virginia law, particularly in cases where prescriptions document a patient-specific clinical difference. Our ask: Would the board be kind enough to clarify how it interprets key terms and standards so that pharmacies can be compliant and patients can still get the meds they need?

🔗https://bit.ly/4bbBcij

03/05/2026

⏳ Two weeks.

In just 14 days, compounding pharmacy owners and managers from across the country will gather in Austin, TX for APC’s 2026 Owner Summit.

Owner Summit isn't meeting just for the sake of meeting. It’s strategy. It’s resilience. It’s branding, AI, pricing psychology, risk management, and the real-world decisions that could determine whether your pharmacy is stronger five years from now than it is today.

If you’ve been meaning to register, this is your moment.
https://bit.ly/40i5gng

Two weeks. We’ll see you in Austin.

03/04/2026

🚨 New episode drop! Peddling a Fantasy: How Drugmakers Are Misleading State Lawmakers

In the latest episode of Essential: The Pharmacy Compounding Podcast, Andrew Kantor and APC's CEO Scott Brunner break down how some drug manufacturers are pushing misleading narratives at the state level — including efforts to restrict compounding and confusion around GLP-1 drugs — and why these tactics matter for licensed compounding pharmacies and patients who need access to compounded medications.

Tune in to hear the facts, get APC’s perspective, and understand what’s at stake for your practice and patient access to personalized therapies.

🎧 Podbean: https://bit.ly/4rbVvC3
🎧 Spotify: https://bit.ly/4cmwmAW
🎧 Youtube: https://bit.ly/4liUWoH
🎧 Apple: https://apple.co/4785qkU

03/04/2026

If you’ve ever stared at a Certificate of Analysis and thought, “Okay… but what does this actually mean for my formula?” — this session is for you.

Join Vanessa Pinheiro and Matthew Johnson for a practical, step-by-step breakdown of how to interpret CoAs for accurate pharmaceutical compounding.
We’re talking real-world application:

✔️ Using assay values, water content, and loss on drying
✔️ Converting salt forms to base equivalents
✔️ Performing dilution calculations correctly
✔️ Avoiding common (and costly) compounding errors
✔️ Understanding antibiotic monographs and potency expressions before you compound

This isn’t theory. It’s the math and decision-making that directly impact your final concentration, dosing, and patient safety.

If precision matters in your lab (and it does), you’ll want to be in this room.

Register now and bring your calculator.
https://bit.ly/3NhqPBq

03/04/2026

APC on the road!

Tenille Davis, APC’s Chief Advocacy Officer, is joined by APC Board members Gina Besteman and Kristen Youngdahl in Denver, CO preparing for tomorrow’s hearing on the Colorado Senate bill that would restrict compounding in The Centennial State. Today, along with our friends from OFA, they will be in meetings briefing lawmakers about compounding.

This is your advocacy team at work for you.

03/03/2026

Over the past year, FDA has issued dozens of warning letters tied to the marketing of compounded GLP-1 products, particularly where pharmacies or telehealth companies made statements that were misleading or blurred the distinction between compounded and FDA-approved drugs.

Marketing should always be truthful, non-misleading, and clearly distinguish compounded medications from FDA-approved products. Avoid claims of equivalence, superiority, or safety comparisons unless they are fully supported and appropriate. FDA has made clear that warning letters will continue where advertising crosses the line.

Good marketing protects your patients, and your practice.

APC has a tool to help you stay in check, download that today.
https://bit.ly/4b07sVl

03/02/2026

March is here, and you know what that means: It’s time to get started on your application for the APC Fellows Program.

Are you worthy? We hope so; becoming a Fellow is the highest distinction APC awards. It distinguishes pharmacists and pharmacy technicians who are exemplary in their professionalism — and in their commitment to the practice of pharmacy compounding. APC Fellows meet stringent requirements that showcase their commitment to patient care through quality pharmacy compounding and the highest ethical and professional standards.

The application requirements are stringent, too. They’ll take more than a couple of days to pull everything together. The deadline to apply for 2026 induction is March 31, 2026, so review the available information and start your application now.

https://bit.ly/4r2fdzZ

02/27/2026

Fantasies shouldn’t inform policy. Writing on LinkedIn, APC’s Scott Brunner takes drugmakers to task for the dark fantasy they’re peddling to state legislatures: the idea that “compounding pharmacies are a shadow supply chain, GLP-1 compounding is inherently suspect, and the only way to protect patients is to impose sweeping new restrictions dressed up as ‘anti-counterfeiting’ policy.” More importantly, he links to two APC white papers that should be acting as reality checks for policymakers who are biting this particular poison apple.

🔗 https://bit.ly/4aGA0Et

Everything over the counter! All at once! FDA Commissioner Marty Makary told CNBC this week that he believes every drug should be over the counter unless it’s unsafe, addictive, or requires monitoring. Does that include GLP-1s? Depends on the rumors you listen to. (Makary’s comment isn’t a shock; he alluded to the same idea back in December.)

🔗 https://bit.ly/4rM8JGM

Bill would “enhance” 503Bs. A bill introduced in Congress — H.R. 7528 — would “amend section 503B of the Federal Food, Drug, and Cosmetic Act to enhance the ability of outsourcing facilities to mitigate drug shortages by allowing a short-term period to continue supplying the market after a drug is in shortage.” That description says it all, and it’s a bill we wholeheartedly support.

🔗 https://bit.ly/3MUJKBY

02/26/2026

APC’s Owner Summit is nearing capacity — and we may hit “Sold Out” soon. If you’ve been meaning to register, this is your sign.

Our room block is full and the host hotel is sold out (we know 😅). But we’ve posted a list of walkable nearby hotels at https://bit.ly/4rEcbmD under “Hotel Reservations.”

Bottom line:
👉 Register now. https://bit.ly/4rEcbmD
👉 Book your hotel ASAP.

FOMO isn’t a business strategy. See you at OS.

02/25/2026

📣 Last call! Tomorrow is this month's CE webinar! 🐶🦜🐱

Want to go beyond the basics and learn how compounding can help companion AND exotic animals thrive? Then you don’t want to miss this!

✨ Join the “Tailored Treatments: Compounding for Companion and Exotic Animals” webinar on Feb. 26 at 2 PM EST — where we’ll dive into species-specific formulation tips, regulatory insights, real-world case examples, and more. Whether it’s a finicky feline or a quirky parrot, we’ve got you (and them) covered. 🐾

💡 Why register?
➡️ Practical compounding know-how
➡️ Expert tips on formulating safe, stable meds for all kinds of pets
➡️ Learn how to work smoothly with veterinarians
➡️ CE credit eligible! 🎓

👉 Don’t let this one slip by — register now and customize care that wags tails (and swishes feathers)! 🧪✨

https://bit.ly/4cezgrj

02/23/2026

🔥 Hot off the press: APC’s 2025–2026 Snapshot of Pharmacy Compounding in America

Our newest Snapshot delivers a sharp, data-driven look at pharmacy compounding in the U.S. — especially 503A practice — and it’s built to share with policymakers, media, prescribers, and decision-makers who need the facts.

Commissioned by APC and conducted by the Center for Business Research at the University of Mary Washington, the report reflects insights from 600+ compounding professionals nationwide. Special thanks to APC corporate patrons Fagron, Medisca, and PCCA for their support.

If you’ve been looking for credible, current data on compounding’s impact — this is it.

Here's a sneak peek:

➡️ The median 503A compounding pharmacy dispenses 350 compounded prescriptions a week, and works with 150 different prescribers to dispense 100 unique compounding formulations.

➡️ The median 503B outsourcing facility provides jobs for 30 people.

➡️ 80% of pharmacies and facilities that compound non-sterile preparations do so for both human and veterinary use.

➡️ Hormone replacement therapy is the most popular compounded formulation, making up an average of 36% of therapies dispensed.

https://bit.ly/4kRMjRD

02/20/2026

APC’s newest Bronze Corporate Patrons are MDI Membrane Technologies and OpenLoop. You can read more about each and check out all our Corporate Patrons on our site.

Like Wile E. Coyote chasing the Roadrunner, drugmakers keep taking compounding pharmacies to court … and keep running into a brick wall. The reason is always the same: Courts won’t let the company use US unfair-competition law to sneak past Article III of the Constitution as they keeps trying to do. Once more, with feeling: Only the FDA has standing to bring suits alleging violations of the Food, Drug, and Cosmetic Act. The latest case pitted Lilly against Willow Health Services. The judge granted Willow’s request for dismissal with prejudice, meaning the case is over and done. (Feel like diving into the legalese, or want to ask an AI to summarize it? Here’s the full decision as a 13-page PDF. Enjoy.)

https://bit.ly/4b1VawQ

“Physicians,” says the American College of Physicians, “Are Not Providers.” Why not? Because an ACP paper says the term “is detrimental to the patient-physician relationship and undermines physicians’ ethical obligations.” Bless their hearts, you can’t make this stuff up. Our take: To quote Dr. Hibbert from the Simpsons, “Hillbillies prefer to be called ‘sons of the soil,’ but it ain’t gonna happen.”

https://bit.ly/4kMf821

Alliance for Pharmacy Compounding

03/06/2026

03/05/2026

03/04/2026

03/04/2026

03/04/2026

03/03/2026

03/02/2026

02/27/2026

02/26/2026

02/25/2026

02/23/2026

02/20/2026

Address

Telephone

Website

Alerts

Shortcuts

Share